| Factors associated with durable EFS in adult B-cell ALL patients achieving MRD-negative CR after CD19 CAR T-cell therapy KA Hay, J Gauthier, AV Hirayama, JM Voutsinas, Q Wu, D Li, TA Gooley, ... Blood, The Journal of the American Society of Hematology 133 (15), 1652-1663, 2019 | 339 | 2019 |
| The response to lymphodepletion impacts PFS in patients with aggressive non-Hodgkin lymphoma treated with CD19 CAR T cells AV Hirayama, J Gauthier, KA Hay, JM Voutsinas, Q Wu, T Gooley, D Li, ... Blood, The Journal of the American Society of Hematology 133 (17), 1876-1887, 2019 | 285 | 2019 |
| γ-Secretase inhibition increases efficacy of BCMA-specific chimeric antigen receptor T cells in multiple myeloma MJ Pont, T Hill, GO Cole, JJ Abbott, J Kelliher, AI Salter, M Hudecek, ... Blood, The Journal of the American Society of Hematology 134 (19), 1585-1597, 2019 | 272 | 2019 |
| Cubic splines to model relationships between continuous variables and outcomes: a guide for clinicians J Gauthier, QV Wu, TA Gooley Bone marrow transplantation 55 (4), 675-680, 2020 | 271 | 2020 |
| Late events after treatment with CD19-targeted chimeric antigen receptor modified T cells A Cordeiro, ED Bezerra, AV Hirayama, JA Hill, QV Wu, J Voutsinas, ... Biology of Blood and Marrow Transplantation 26 (1), 26-33, 2020 | 264 | 2020 |
| Institutional clinical trial accrual volume and survival of patients with head and neck cancer EJ Wuthrick, Q Zhang, M Machtay, DI Rosenthal, PF Nguyen-Tan, A Fortin, ... Journal of Clinical Oncology 33 (2), 156, 2015 | 249 | 2015 |
| High rate of durable complete remission in follicular lymphoma after CD19 CAR-T cell immunotherapy AV Hirayama, J Gauthier, KA Hay, JM Voutsinas, Q Wu, BS Pender, ... Blood, The Journal of the American Society of Hematology 134 (7), 636-640, 2019 | 166 | 2019 |
| A phase II trial of pembrolizumab and vorinostat in recurrent metastatic head and neck squamous cell carcinomas and salivary gland cancer CP Rodriguez, Q Wu, J Voutsinas, JR Fromm, X Jiang, VG Pillarisetty, ... Clinical Cancer Research 26 (4), 837-845, 2020 | 143 | 2020 |
| Derivation and validation of a risk assessment model for immunomodulatory drug–associated thrombosis among patients with multiple myeloma A Li, Q Wu, S Luo, GS Warnick, NA Zakai, EN Libby, BF Gage, DA Garcia, ... Journal of the National Comprehensive Cancer Network 17 (7), 840-847, 2019 | 126 | 2019 |
| External validation of the PLASMIC score: a clinical prediction tool for thrombotic thrombocytopenic purpura diagnosis and treatment A Li, PR Khalighi, Q Wu, DA Garcia Journal of Thrombosis and Haemostasis 16 (1), 164-169, 2018 | 116 | 2018 |
| Patient-reported neuropsychiatric outcomes of long-term survivors after chimeric antigen receptor T cell therapy J Ruark, E Mullane, N Cleary, A Cordeiro, ED Bezerra, V Wu, J Voutsinas, ... Biology of Blood and Marrow Transplantation 26 (1), 34-43, 2020 | 110 | 2020 |
| Pembrolizumab with R‐CHOP in previously untreated diffuse large B‐cell lymphoma: potential for biomarker driven therapy SD Smith, BG Till, MS Shadman, RC Lynch, AJ Cowan, QV Wu, ... British journal of haematology 189 (6), 1119-1126, 2020 | 93 | 2020 |
| Severe cytokine release syndrome is associated with hematologic toxicity following CD19 CAR T-cell therapy KR Juluri, QV Wu, J Voutsinas, J Hou, AV Hirayama, E Mullane, N Miles, ... Blood Advances 6 (7), 2055-2068, 2022 | 89 | 2022 |
| Efficacy and safety of fully human Bcma CAR T cells in combination with a gamma secretase inhibitor to increase Bcma surface expression in patients with relapsed or refractory … AJ Cowan, M Pont, BD Sather, CJ Turtle, BG Till, AM Nagengast, ... Blood 134, 204, 2019 | 65 | 2019 |
| Transplant-associated thrombotic microangiopathy is a multifactorial disease unresponsive to immunosuppressant withdrawal A Li, Q Wu, C Davis, KS Kirtane, PD Pham, ML Sorror, SJ Lee, AK Gopal, ... Biology of Blood and Marrow Transplantation 25 (3), 570-576, 2019 | 55 | 2019 |
| The vascular bone marrow niche influences outcome in chronic myeloid leukemia via the E-selectin-SCL/TAL1-CD44 axis PS Godavarthy, R Kumar, SC Herkt, RS Pereira, N Hayduk, ... Haematologica 105 (1), 136, 2020 | 53 | 2020 |
| Multispecific targeting with synthetic ankyrin repeat motif chimeric antigen receptors A Balakrishnan, A Rajan, AI Salter, PL Kosasih, Q Wu, J Voutsinas, ... Clinical Cancer Research 25 (24), 7506-7516, 2019 | 48 | 2019 |
| Prospective study of serial 18F-FDG PET and 18F-fluoride PET to predict time to skeletal-related events, time to progression, and survival in patients with bone-dominant … LM Peterson, J O’Sullivan, QV Wu, A Novakova-Jiresova, I Jenkins, ... Journal of Nuclear Medicine 59 (12), 1823-1830, 2018 | 47 | 2018 |
| Impact of CD19 CAR T-cell product type on outcomes in relapsed or refractory aggressive B-NHL J Gauthier, N Gazeau, AV Hirayama, JA Hill, V Wu, A Cearley, P Perkins, ... Blood, The Journal of the American Society of Hematology 139 (26), 3722-3731, 2022 | 44 | 2022 |
| Hematopoietic cell transplantation after CD19 chimeric antigen receptor T cell-induced acute lymphoblastic leukemia remission confers a leukemia-free survival advantage C Summers, QV Wu, C Annesley, M Bleakley, A Dahlberg, ... Transplantation and Cellular Therapy 28 (1), 21-29, 2022 | 43 | 2022 |
Jenna VoutsinasFred Hutchinson Cancer Research CenterVerified email at fredhutch.org
